Single User License
INR 475170
Site License
INR 950341
Corporate User License
INR 1425511

Service Tax Additional

select a format
Price

Single User License
USD 6995
Site License
USD 13990
Corporate User License
USD 20985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Allergic Rhinitis-5EU Drug Forecast and Market Analysis to 2024

Allergic Rhinitis-5EU Drug Forecast and Market Analysis to 2024


  Request for Sample Report

Executive Summary

Allergic Rhinitis-5EU Drug Forecast and Market Analysis to 2024

Summary

AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

In 2014, the base-year of the forecast period, sales of AR products in the 5EU totaled USD 2.53 billion. The 5EU AR market will remain stagnant, with no major events occurring over the 10-year forecast period. There are no pipeline AR products set to launch in the 5EU during this time. The patent expiries of the best-selling prescription INCS, Nasonex and Nasacort, will be the events that have the most negative impact on the 5EU AR market during the forecast period.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in 5EU from 2014-2024.

Analysis of the impact of key events as well the drivers and restraints affecting 5EU Allergic Rhinitis market.

Reasons To Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2014-2024 in 5EU.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 10

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.2 Symptoms 14

3.3 Classification 15

3.3.1 Seasonal and Perennial AR 15

3.3.2 ARIA Classification of AR 15

3.4 Diagnosis 16

3.5 Quality of Life 18

4 Disease Management 19

4.1 Diagnosis and Treatment Overview 19

4.1.1 Diagnosis 19

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20

4.1.3 Clinical Practice 23

4.2 France 32

4.3 Germany 34

4.4 Italy 38

4.5 Spain 40

4.6 UK 42

5 Competitive Assessment 44

5.1 Overview 44

5.2 Oral H1 Antihistamines 48

5.2.1 Overview 48

5.2.2 Efficacy 57

5.2.3 Safety 58

5.2.4 SWOT Analysis 60

5.2.5 Forecast 61

5.3 Intranasal Antihistamines 61

5.4 Intranasal Corticosteroids 64

5.4.1 Overview 64

5.4.2 Efficacy 71

5.4.3 Safety 73

5.4.4 SWOT Analysis 74

5.4.5 Forecast 75

5.5 Combination Intranasal Corticosteroids/Antihistamines 75

5.5.1 Dymista 75

5.6 Decongestants 84

5.6.1 Overview 84

5.7 Intranasal Anticholinergics 87

5.7.1 Overview 87

5.8 Leukotriene Receptor Antagonists 88

5.8.1 Overview 88

5.9 Cromones 91

5.9.1 Overview 91

5.10 Thromboxane A2 Receptor Antagonists 92

5.10.1 Overview 92

5.11 TH2 Cytokine Inhibitors 93

5.11.1 Overview 93

6 Unmet Need and Opportunity 94

6.1 Overview 94

6.2 Pharmacist Education 96

6.2.1 Unmet Need 96

6.2.2 Gap Analysis 98

6.2.3 Opportunity 99

6.3 Patient Compliance With Intranasal Corticosteroids and Antihistamines 101

6.3.1 Unmet Need 101

6.3.2 Gap Analysis 102

6.3.3 Opportunity 104

6.4 More Convenient and More Patient-Friendly Immunotherapies 107

6.4.1 Unmet Need 107

6.4.2 Gap Analysis 108

6.4.3 Opportunity 110

6.5 Primary Care Physician Education 111

6.5.1 Unmet Need 111

6.5.2 Gap Analysis 113

6.5.3 Opportunity 114

7 Pipeline Assessment 116

7.1 Promising Drugs in Clinical Development 117

7.1.1 S-555739 117

7.1.2 HP-3060 123

8 Market Outlook 128

8.1 5EU 128

8.1.1 Forecast 128

8.1.2 Key Events 132

8.1.3 Drivers and Barriers 132

9 Appendix 141

9.1 Bibliography 141

9.2 Abbreviations 154

9.3 Methodology 159

9.4 Forecasting Methodology 159

9.4.1 Pediatric Allergic Rhinitis Population 159

9.4.2 Diagnosed AR Patients 165

9.4.3 Percentage of Drug-Treated Patients 165

9.4.4 Drugs Included in Each Therapeutic Class 165

9.4.5 Launch and Patent Expiry Dates 168

9.4.6 1General Pricing Assumptions 169

9.4.7 Individual Drug Assumptions 170

9.4.8 Generic Erosion 179

9.4.9 Pricing of Pipeline Agents 179

9.5 Physicians and Specialists Included in This Study 180

9.6 About the Authors 184

9.6.1 Analyst 184

9.6.2 Therapy Area Director 184

9.6.3 Epidemiologist 185

9.6.4 Global Head of Healthcare 185

9.7 About GlobalData 186

9.8 Disclaimer 186

1.2 List of Figures

Figure 1: Immunological Mechanisms Involved in the Early- and Late-Phase Allergic Response 13

Figure 2: ARIA Classification of AR by Duration of Symptoms and Severity 16

Figure 3: Algorithm Used for the Management of AR in the 7MM* 25

Figure 4: Sales for AR in the 5EU by Drug Class, 2014-2024 131

1.1 List of Tables

Table 1: Airborne Allergens That Cause AR 11

Table 2: Common Symptoms of AR 14

Table 3: Treatment Guidelines for AR 21

Table 4: Most Commonly Prescribed Drugs for AR in the 7MM by Class, 2014 22

Table 5: Major Brands of INCS 28

Table 6: Management of AR, Country Profile-France 33

Table 7: Management of AR, Country Profile-Germany 37

Table 8: Management of AR, Country Profile-Italy 39

Table 9: Management of AR Country Profile-Spain 41

Table 10: Management of AR Country Profile-UK 43

Table 11: Effects of Main Drug Classes on AR Symptoms 46

Table 12: Leading Branded Drugs Used to Treat AR, 2014 48

Table 13: Major Brands of Second- and Third-Generation Non-Sedating AHs 54

Table 14: Product Profile-AHs 57

Table 15: Efficacy of Bilastine in Symptomatic SAR Patients Age 12-70 Years 58

Table 16: Safety of Bilastine in Symptomatic SAR Patients Age 12-70 Years 59

Table 17: Oral AHs SWOT Analysis, 2014 60

Table 18: Global Sales Forecasts (USD m) for Oral AHs, 2014-2024 61

Table 19: Major Brands of Intranasal Ahs 63

Table 20: Major Brands of INCS 69

Table 21: Product Profile-INCS 71

Table 22: Efficacy of FP ANS and BDP ANS in AR Patients Age 18-72 Years 72

Table 23: Safety Profile of FP ANS and BDP ANS in AR Patients Age 18-72 Years 73

Table 24: INCS SWOT Analysis, 2014 74

Table 25: Global Sales Forecasts (USD m) for INCS, 2014-2024 75

Table 26: Product Profile-Dymista 80

Table 27: Efficacy of Dymista 81

Table 28: Safety of Dymista 82

Table 29: Dymista SWOT Analysis, 2014 83

Table 30: Global Sales Forecasts (USD m) for Dymista, 2014-2024 84

Table 31: Unmet Need and Opportunity in AR 95

Table 32: Late-Stage Pipeline for AR, 2014 117

Table 33: Product Profile-S-555739 118

Table 34: Completed Clinical Trials of S-555739 in AR Patients 120

Table 35: S-555739 SWOT Analysis, 2014 122

Table 36: Global Sales Forecasts (USD ) for S-555739, 2014-2024 123

Table 37: Product Profile-HP-3060 124

Table 38: HP-3060 SWOT Analysis, 2014 126

Table 39: Global Sales Forecasts (USD ) for HP-3060, 2014-2024 127

Table 40: Sales Forecasts (USD m) for AR in the 5EU, 2014-2024 130

Table 41: Key Events Impacting Sales for AR in the 5EU, 2014-2024 132

Table 42: AR Market-Drivers and Barriers in the 5EU, 2014 132

Table 43: Abbreviations 154

Table 44: Key Launch Dates of the Currently Available AR Therapies 168

Table 45: Key Loss of Exclusivity Dates of the Currently Available AR Therapies 169

Table 46: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 183

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com